752: Tissue Expression and Breed-Related Pharmocogenetics of Cytochrome P450 3A12
Grant Status: Closed
Project Summary
Although many factors influence a patient's response to drug therapy, including the patient's age, disease status, concurrent medications, and others, these are insufficient to explain the wide variation in drug response observed between patients. In humans, genetics has been shown to be an extremely important factor in determining whether or not a patient will experience an adverse drug reaction (ADR). In dogs, many ADRs are known to be breedrelated. That is, drugs that are tolerated by most dogs may cause ADRs in certain breeds. Our research focuses on two important drug metabolizing enzymes in dogs. We have shown that these enzymes are expressed not only in the liver but also in the small intestine. Our CHF supported research project has completed all of its objectives, which has provided critically needed new insights into the expression patterns and genetic variation of CYP3A12 within and among dog breeds. These data have provided the necessary framework for correlating patterns of DNA sequence and structural variation of CYP3A12 with drug metabolizing phenotypes and breed-specific ADRs.
Publication(s)
Help Future Generations of Dogs
Participate in canine health research by providing samples or by enrolling in a clinical trial. Samples are needed from healthy dogs and dogs affected by specific diseases.
